drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00342 | DB00862 | 1,181 | 1,005 | [
"DDInter1770",
"DDInter1918"
] | Terfenadine | Vardenafil | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Moderate | 1 | [
[
[
1181,
24,
1005
]
],
[
[
1181,
23,
112
],
[
112,
63,
1005
]
],
[
[
1181,
24,
1494
],
[
1494,
24,
1005
]
],
[
[
1181,
24,
1133
],
[
1133... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vardenafil"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Vardenafil
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron an... |
DB00852 | DB06203 | 1,445 | 1,002 | [
"DDInter1545",
"DDInter51"
] | Pseudoephedrine | Alogliptin | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
1445,
24,
1002
]
],
[
[
1445,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1445,
6,
12523
],
[
12523,
45,
1002
]
],
[
[
1445,
21,
28787
],
[
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Pseudoephedrine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Alogliptin (Compound)
Pseudoephedrine (Compound) causes Dermatitis (Side Eff... |
DB08826 | DB13007 | 1,292 | 1,060 | [
"DDInter489",
"DDInter642"
] | Deferiprone | Enfortumab vedotin | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Major | 2 | [
[
[
1292,
25,
1060
]
],
[
[
1292,
25,
1593
],
[
1593,
24,
1060
]
],
[
[
1292,
64,
268
],
[
268,
24,
1060
]
],
[
[
1292,
64,
1377
],
[
1377... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
... | Deferiprone may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Deferiprone may lead to a major life threatening interaction when taken with Peginterferon alfa-2b and Peginterferon a... |
DB00630 | DB01050 | 1,485 | 848 | [
"DDInter42",
"DDInter900"
] | Alendronic acid | Ibuprofen | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
1485,
24,
848
]
],
[
[
1485,
21,
28864
],
[
28864,
60,
848
]
],
[
[
1485,
62,
752
],
[
752,
23,
848
]
],
[
[
1485,
23,
1194
],
[
1194,... | [
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Alendronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema multiforme"
],
[
"Erythema multiforme",
... | Alendronic acid (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Ibuprofen (Compound)
Alendronic acid may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effect... |
DB09049 | DB12500 | 1,135 | 283 | [
"DDInter1261",
"DDInter714"
] | Naloxegol | Fedratinib | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
1135,
25,
283
]
],
[
[
1135,
25,
351
],
[
351,
23,
283
]
],
[
[
1135,
64,
1593
],
[
1593,
23,
283
]
],
[
[
1135,
25,
1339
],
[
1339,
... | [
[
[
"Naloxegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Naloxegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may... | Naloxegol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Naloxegol may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a minor interaction... |
DB00106 | DB00529 | 618 | 789 | [
"DDInter4",
"DDInter779"
] | Abarelix | Foscarnet | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Moderate | 1 | [
[
[
618,
24,
789
]
],
[
[
618,
23,
112
],
[
112,
62,
789
]
],
[
[
618,
24,
1494
],
[
1494,
24,
789
]
],
[
[
618,
24,
770
],
[
770,
6... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Foscarnet
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonos... |
DB08934 | DB11901 | 1,200 | 913 | [
"DDInter1695",
"DDInter107"
] | Sofosbuvir | Apalutamide | Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 bein... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1200,
25,
913
]
],
[
[
1200,
63,
126
],
[
126,
24,
913
]
],
[
[
1200,
24,
927
],
[
927,
25,
913
]
],
[
[
1200,
24,
214
],
[
214,
... | [
[
[
"Sofosbuvir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Sofosbuvir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
... | Sofosbuvir may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Sofosbuvir may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafe... |
DB00554 | DB11901 | 1,027 | 913 | [
"DDInter1478",
"DDInter107"
] | Piroxicam | Apalutamide | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1027,
24,
913
]
],
[
[
1027,
63,
254
],
[
254,
24,
913
]
],
[
[
1027,
25,
1468
],
[
1468,
24,
913
]
],
[
[
1027,
24,
877
],
[
877,
... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Piroxicam may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a m... |
DB00286 | DB01110 | 380 | 86 | [
"DDInter439",
"DDInter1209"
] | Conjugated estrogens | Miconazole | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
380,
24,
86
]
],
[
[
380,
6,
4973
],
[
4973,
45,
86
]
],
[
[
380,
21,
29122
],
[
29122,
60,
86
]
],
[
[
380,
24,
1101
],
[
1101,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound b... | Conjugated estrogens (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Miconazole (Compound)
Conjugated estrogens (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Miconazole (Compound)
Conjugated estrogens may cause a moderate interaction that could exace... |
DB01073 | DB01177 | 1,488 | 77 | [
"DDInter745",
"DDInter904"
] | Fludarabine | Idarubicin | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
1488,
24,
77
]
],
[
[
1488,
5,
11555
],
[
11555,
44,
77
]
],
[
[
1488,
21,
28931
],
[
28931,
60,
77
]
],
[
[
1488,
62,
646
],
[
646,
... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Fludarabine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Dise... | Fludarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Idarubicin (Compound)
Fludarabine (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Idarubicin (Compound)
Fludarabine may cause a minor interaction that can limit clinical effec... |
DB00377 | DB00497 | 1,494 | 828 | [
"DDInter1382",
"DDInter1366"
] | Palonosetron | Oxycodone | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Moderate | 1 | [
[
[
1494,
24,
828
]
],
[
[
1494,
63,
421
],
[
421,
1,
828
]
],
[
[
1494,
24,
314
],
[
314,
1,
828
]
],
[
[
1494,
24,
560
],
[
560,
4... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Oxycodone (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine (Compound) resembles Oxycodone (Co... |
DB05239 | DB11979 | 866 | 1,320 | [
"DDInter425",
"DDInter625"
] | Cobimetinib | Elagolix | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
866,
24,
1320
]
],
[
[
866,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
866,
64,
1249
],
[
1249,
24,
1320
]
],
[
[
866,
25,
129
],
[
129,
... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Cobimetinib may lead to a major life threatening interaction when taken with Nafcillin and Nafcillin may caus... |
DB01281 | DB06168 | 881 | 1,531 | [
"DDInter5",
"DDInter281"
] | Abatacept | Canakinumab | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
881,
24,
1531
]
],
[
[
881,
23,
1193
],
[
1193,
62,
1531
]
],
[
[
881,
62,
1461
],
[
1461,
23,
1531
]
],
[
[
881,
24,
1270
],
[
1270,
... | [
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Abatacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Abatacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Abatacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitami... |
DB06317 | DB14409 | 1,626 | 1,129 | [
"DDInter630",
"DDInter867"
] | Elotuzumab | Human adenovirus e serotype 4 strain cl-68578 antigen | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1626,
24,
1129
]
],
[
[
1626,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1626,
63,
1683
],
[
1683,
24,
1129
]
],
[
[
1626,
24,
1468
],
[
14... | [
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Elotuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Elotuzumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Elotuzumab may cause a moderate interaction that could exacerbate diseases when take... |
DB00188 | DB00349 | 168 | 902 | [
"DDInter222",
"DDInter401"
] | Bortezomib | Clobazam | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Minor | 0 | [
[
[
168,
23,
902
]
],
[
[
168,
25,
695
],
[
695,
1,
902
]
],
[
[
168,
23,
1335
],
[
1335,
1,
902
]
],
[
[
168,
6,
10215
],
[
10215,
... | [
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clobazam"
]
],
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
... | Bortezomib may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Clobazam (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Clobazam (Compound)
Bortezomib (Compo... |
DB05812 | DB12941 | 1,374 | 466 | [
"DDInter8",
"DDInter481"
] | Abiraterone | Darolutamide | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
1374,
23,
466
]
],
[
[
1374,
63,
1622
],
[
1622,
23,
466
]
],
[
[
1374,
62,
34
],
[
34,
23,
466
]
],
[
[
1374,
25,
351
],
[
351,
... | [
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
... | Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Fosamprenavir and... |
DB00404 | DB09098 | 523 | 98 | [
"DDInter54",
"DDInter1700"
] | Alprazolam | Somatrem | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
523,
24,
98
]
],
[
[
523,
63,
608
],
[
608,
23,
98
]
],
[
[
523,
24,
159
],
[
159,
63,
98
]
],
[
[
523,
23,
1573
],
[
1573,
24,
... | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrect... |
DB00502 | DB01041 | 1,300 | 770 | [
"DDInter853",
"DDInter1789"
] | Haloperidol | Thalidomide | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1300,
24,
770
]
],
[
[
1300,
6,
7524
],
[
7524,
45,
770
]
],
[
[
1300,
21,
29177
],
[
29177,
60,
770
]
],
[
[
1300,
25,
609
],
[
609,
... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Haloperidol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound... | Haloperidol (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Haloperidol (Compound) causes Musculoskeletal stiffness (Side Effect) and Musculoskeletal stiffness (Side Effect) is caused by Thalidomide (Compound)
Haloperidol may lead to a major life threatening interaction when taken wi... |
DB00795 | DB01124 | 50 | 1,411 | [
"DDInter1725",
"DDInter1828"
] | Sulfasalazine | Tolbutamide | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
50,
24,
1411
]
],
[
[
50,
24,
959
],
[
959,
40,
1411
]
],
[
[
50,
63,
245
],
[
245,
40,
1411
]
],
[
[
50,
24,
1296
],
[
1296,
63... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Co... |
DB01254 | DB08871 | 1,213 | 36 | [
"DDInter484",
"DDInter666"
] | Dasatinib | Eribulin | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1213,
24,
36
]
],
[
[
1213,
18,
5816
],
[
5816,
45,
36
]
],
[
[
1213,
63,
122
],
[
122,
23,
36
]
],
[
[
1213,
62,
1247
],
[
1247,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Dasatinib",
"{u} (Compound) downregulates {v} (Gene)",
"TUBB4B"
],
[
"TUBB4B",
"{u} (Gene) is bound by {v} (Compoun... | Dasatinib (Compound) downregulates TUBB4B (Gene) and TUBB4B (Gene) is bound by Eribulin (Compound)
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Eribulin
Dasatinib may cause ... |
DB00353 | DB06663 | 588 | 1,154 | [
"DDInter1187",
"DDInter1398"
] | Methylergometrine | Pasireotide | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
588,
24,
1154
]
],
[
[
588,
63,
966
],
[
966,
40,
1154
]
],
[
[
588,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
588,
1,
826
],
[
826,
... | [
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
... | Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Methylergometrine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Methylergometrine ... |
DB00636 | DB01098 | 429 | 14 | [
"DDInter408",
"DDInter1622"
] | Clofibrate | Rosuvastatin | A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Major | 2 | [
[
[
429,
25,
14
]
],
[
[
429,
6,
8374
],
[
8374,
45,
14
]
],
[
[
429,
25,
126
],
[
126,
24,
14
]
],
[
[
429,
24,
629
],
[
629,
24,
... | [
[
[
"Clofibrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Clofibrate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rosuv... | Clofibrate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rosuvastatin (Compound)
Clofibrate may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Clofibrate may cause a moderate i... |
DB00443 | DB09564 | 251 | 1,296 | [
"DDInter195",
"DDInter930"
] | Betamethasone | Insulin degludec | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
251,
24,
1296
]
],
[
[
251,
40,
1103
],
[
1103,
23,
1296
]
],
[
[
251,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
251,
23,
659
],
[
659,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cau... | Betamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interactio... |
DB00207 | DB00938 | 1,570 | 455 | [
"DDInter157",
"DDInter1635"
] | Azithromycin | Salmeterol | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1570,
24,
455
]
],
[
[
1570,
24,
688
],
[
688,
63,
455
]
],
[
[
1570,
6,
8374
],
[
8374,
45,
455
]
],
[
[
1570,
21,
29024
],
[
29024,
... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
... | Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Azithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound)
Azithromycin (... |
DB08881 | DB09039 | 868 | 1,670 | [
"DDInter1925",
"DDInter629"
] | Vemurafenib | Eliglustat | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
868,
24,
1670
]
],
[
[
868,
62,
479
],
[
479,
23,
1670
]
],
[
[
868,
23,
1135
],
[
1135,
62,
1670
]
],
[
[
868,
63,
121
],
[
121,
... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Vemurafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
... | Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may... |
DB00712 | DB01208 | 1,274 | 945 | [
"DDInter763",
"DDInter1705"
] | Flurbiprofen | Sparfloxacin | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Moderate | 1 | [
[
[
1274,
24,
945
]
],
[
[
1274,
24,
739
],
[
739,
1,
945
]
],
[
[
1274,
63,
1176
],
[
1176,
1,
945
]
],
[
[
1274,
21,
29006
],
[
29006,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparflox... |
DB01599 | DB12245 | 1,232 | 823 | [
"DDInter1523",
"DDInter1863"
] | Probucol | Triclabendazole | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
1232,
24,
823
]
],
[
[
1232,
62,
112
],
[
112,
23,
823
]
],
[
[
1232,
63,
1010
],
[
1010,
24,
823
]
],
[
[
1232,
24,
28
],
[
28,
... | [
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Probucol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Probucol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mef... |
DB00364 | DB01203 | 417 | 699 | [
"DDInter1717",
"DDInter1255"
] | Sucralfate | Nadolol | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Minor | 0 | [
[
[
417,
23,
699
]
],
[
[
417,
23,
729
],
[
729,
1,
699
]
],
[
[
417,
21,
28882
],
[
28882,
60,
699
]
],
[
[
417,
24,
1384
],
[
1384,
... | [
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nadolol"
]
],
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Penbutolol"
],
[
"Pe... | Sucralfate may cause a minor interaction that can limit clinical effects when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Sucralfate (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Nadolol (Compound)
Sucralfate may cau... |
DB00694 | DB01268 | 51 | 1,151 | [
"DDInter485",
"DDInter1731"
] | Daunorubicin | Sunitinib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
51,
24,
1151
]
],
[
[
51,
18,
2284
],
[
2284,
45,
1151
]
],
[
[
51,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
51,
7,
2602
],
[
2602,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Daunorubicin",
"{u} (Compound) downregulates {v} (Gene)",
"PRPF4"
],
[
"PRPF4",
"{u} (Gene) is bound by {v} (Co... | Daunorubicin (Compound) downregulates PRPF4 (Gene) and PRPF4 (Gene) is bound by Sunitinib (Compound)
Daunorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Daunorubicin (Compound) upregulates PTK2B (Gene) and PTK2B (Gene) is bound by Sunitinib (Compound)
Daunorubicin (Compound) dow... |
DB00467 | DB01030 | 1,467 | 869 | [
"DDInter644",
"DDInter1835"
] | Enoxacin | Topotecan | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Minor | 0 | [
[
[
1467,
23,
869
]
],
[
[
1467,
23,
613
],
[
613,
24,
869
]
],
[
[
1467,
7,
2759
],
[
2759,
46,
869
]
],
[
[
1467,
6,
3199
],
[
3199,
... | [
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Topotecan"
]
],
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Irinotecan"
],
[
"Irin... | Enoxacin may cause a minor interaction that can limit clinical effects when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Enoxacin (Compound) upregulates CEBPA (Gene) and CEBPA (Gene) is upregulated by Topotecan (Compound)
Enoxacin (Compou... |
DB00881 | DB01067 | 954 | 959 | [
"DDInter1554",
"DDInter826"
] | Quinapril | Glipizide | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
954,
24,
959
]
],
[
[
954,
63,
245
],
[
245,
40,
959
]
],
[
[
954,
24,
1411
],
[
1411,
1,
959
]
],
[
[
954,
21,
28698
],
[
28698,
... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
... |
DB00717 | DB01124 | 1,197 | 1,411 | [
"DDInter1312",
"DDInter1828"
] | Norethisterone | Tolbutamide | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1197,
24,
1411
]
],
[
[
1197,
24,
959
],
[
959,
40,
1411
]
],
[
[
1197,
63,
245
],
[
245,
40,
1411
]
],
[
[
1197,
6,
10215
],
[
10215,... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (... |
DB00083 | DB01172 | 677 | 416 | [
"DDInter225",
"DDInter1004"
] | Botulinum toxin type A | Kanamycin | In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperf... | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Major | 2 | [
[
[
677,
25,
416
]
],
[
[
677,
25,
1481
],
[
1481,
25,
416
]
],
[
[
677,
25,
1448
],
[
1448,
35,
416
]
],
[
[
677,
25,
1481
],
[
1481,
... | [
[
[
"Botulinum toxin type A",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
]
],
[
[
"Botulinum toxin type A",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polymyxin B"
],
[
"P... | Botulinum toxin type A may lead to a major life threatening interaction when taken with Polymyxin B and Polymyxin B may lead to a major life threatening interaction when taken with Kanamycin
Botulinum toxin type A may lead to a major life threatening interaction when taken with Streptomycin and Streptomycin (Compound) ... |
DB00358 | DB01236 | 1,010 | 679 | [
"DDInter1140",
"DDInter1664"
] | Mefloquine | Sevoflurane | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
1010,
24,
679
]
],
[
[
1010,
24,
1262
],
[
1262,
40,
679
]
],
[
[
1010,
6,
8374
],
[
8374,
45,
679
]
],
[
[
1010,
21,
28751
],
[
28751... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Mefloquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sevoflurane (Compound)
Mefloquine (Compound) causes Convulsion (Side Effect) and Convul... |
DB00279 | DB00448 | 1,152 | 1,215 | [
"DDInter1074",
"DDInter1022"
] | Liothyronine | Lansoprazole | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Moderate | 1 | [
[
[
1152,
24,
1215
]
],
[
[
1152,
24,
379
],
[
379,
1,
1215
]
],
[
[
1152,
63,
837
],
[
837,
1,
1215
]
],
[
[
1152,
6,
4973
],
[
4973,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole (Compound) resembles Lansoprazole (Compound)
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole (Compound) resembles Lansoprazo... |
DB08816 | DB14730 | 578 | 1,412 | [
"DDInter1802",
"DDInter264"
] | Ticagrelor | Calaspargase pegol | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
578,
24,
1412
]
],
[
[
578,
64,
792
],
[
792,
24,
1412
]
],
[
[
578,
24,
159
],
[
159,
24,
1412
]
],
[
[
578,
63,
1347
],
[
1347,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"R... | Ticagrelor may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrec... |
DB01319 | DB12941 | 34 | 466 | [
"DDInter777",
"DDInter481"
] | Fosamprenavir | Darolutamide | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
34,
23,
466
]
],
[
[
34,
23,
1374
],
[
1374,
23,
466
]
],
[
[
34,
25,
351
],
[
351,
23,
466
]
],
[
[
34,
1,
1091
],
[
1091,
23,
... | [
[
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
... | Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fosamprenavir may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may ... |
DB01018 | DB05812 | 1,364 | 1,374 | [
"DDInter847",
"DDInter8"
] | Guanfacine | Abiraterone | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1364,
24,
1374
]
],
[
[
1364,
6,
8374
],
[
8374,
45,
1374
]
],
[
[
1364,
21,
28661
],
[
28661,
60,
1374
]
],
[
[
1364,
25,
760
],
[
76... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Guanfacine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Guanfacine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound)
Guanfacine (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Abiraterone (Compound)
Guanfacine may lead to a major life threatening interaction when taken with Cobi... |
DB00026 | DB01023 | 1,184 | 409 | [
"DDInter94",
"DDInter716"
] | Anakinra | Felodipine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Moderate | 1 | [
[
[
1184,
24,
409
]
],
[
[
1184,
24,
376
],
[
376,
40,
409
]
],
[
[
1184,
24,
1428
],
[
1428,
1,
409
]
],
[
[
1184,
24,
1031
],
[
1031,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) resembles Felodipine (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Felodipine (Compound)
Anak... |
DB01148 | DB09488 | 1,128 | 103 | [
"DDInter738",
"DDInter23"
] | Flavoxate | Acrivastine | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1128,
24,
103
]
],
[
[
1128,
63,
85
],
[
85,
24,
103
]
],
[
[
1128,
24,
537
],
[
537,
24,
103
]
],
[
[
1128,
64,
1621
],
[
1621,
... | [
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
... | Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine ma... |
DB01246 | DB01259 | 820 | 392 | [
"DDInter45",
"DDInter1024"
] | Alimemazine | Lapatinib | A phenothiazine derivative that is used as an antipruritic. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
820,
24,
392
]
],
[
[
820,
6,
8374
],
[
8374,
45,
392
]
],
[
[
820,
18,
15501
],
[
15501,
57,
392
]
],
[
[
820,
21,
28643
],
[
28643,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Alimemazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Alimemazine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Lapatinib (Compound)
Alimemazine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Lapatinib (Compound)
... |
DB01254 | DB11837 | 1,213 | 1,297 | [
"DDInter484",
"DDInter1351"
] | Dasatinib | Osilodrostat | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
1213,
24,
1297
]
],
[
[
1213,
23,
1135
],
[
1135,
23,
1297
]
],
[
[
1213,
62,
112
],
[
112,
23,
1297
]
],
[
[
1213,
63,
222
],
[
222,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Dasatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Dasatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazo... |
DB00434 | DB01619 | 13 | 830 | [
"DDInter459",
"DDInter1441"
] | Cyproheptadine | Phenindamine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
13,
24,
830
]
],
[
[
13,
63,
1251
],
[
1251,
1,
830
]
],
[
[
13,
40,
11286
],
[
11286,
1,
830
]
],
[
[
13,
1,
11321
],
[
11321,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine (Compound) resembles Phenindamine (Compound)
Cyproheptadine (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Phenindamine (Compound)
Cyproheptadine (Compou... |
DB01128 | DB04845 | 918 | 309 | [
"DDInter204",
"DDInter1001"
] | Bicalutamide | Ixabepilone | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
918,
24,
309
]
],
[
[
918,
6,
8374
],
[
8374,
45,
309
]
],
[
[
918,
18,
16974
],
[
16974,
45,
309
]
],
[
[
918,
21,
28736
],
[
28736,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Bicalutamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Bicalutamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Bicalutamide (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is bound by Ixabepilone (Compound)
Bicalutamide (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Ixabepilone (Compoun... |
DB00035 | DB00344 | 1,314 | 1,302 | [
"DDInter507",
"DDInter1543"
] | Desmopressin | Protriptyline | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Moderate | 1 | [
[
[
1314,
24,
1302
]
],
[
[
1314,
24,
413
],
[
413,
1,
1302
]
],
[
[
1314,
24,
109
],
[
109,
40,
1302
]
],
[
[
1314,
21,
28717
],
[
28717,... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
],
... | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline and Maprotiline (Compound) resembles Protriptyline (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) resembles Protriptyline... |
DB00992 | DB04951 | 842 | 187 | [
"DDInter1182",
"DDInter1477"
] | Methyl aminolevulinate (topical) | Pirfenidone | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Moderate | 1 | [
[
[
842,
24,
187
]
],
[
[
842,
63,
1419
],
[
1419,
24,
187
]
],
[
[
842,
24,
9
],
[
9,
24,
187
]
],
[
[
842,
24,
33
],
[
33,
25,
... | [
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Im... | Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00762 | DB15091 | 613 | 676 | [
"DDInter973",
"DDInter1901"
] | Irinotecan | Upadacitinib | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
613,
25,
676
]
],
[
[
613,
63,
1461
],
[
1461,
23,
676
]
],
[
[
613,
24,
1430
],
[
1430,
24,
676
]
],
[
[
613,
63,
1249
],
[
1249,
... | [
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipule... |
DB00294 | DB00912 | 1,336 | 473 | [
"DDInter701",
"DDInter1581"
] | Etonogestrel | Repaglinide | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1336,
24,
473
]
],
[
[
1336,
6,
8374
],
[
8374,
45,
473
]
],
[
[
1336,
21,
28757
],
[
28757,
60,
473
]
],
[
[
1336,
24,
609
],
[
609,
... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Etonogestrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Etonogestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Repaglinide (Compound)
Etonogestrel (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Repaglinide (Compound)
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Clarithromy... |
DB01268 | DB06699 | 1,151 | 774 | [
"DDInter1731",
"DDInter493"
] | Sunitinib | Degarelix | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
1151,
24,
774
]
],
[
[
1151,
63,
521
],
[
521,
1,
774
]
],
[
[
1151,
21,
28703
],
[
28703,
60,
774
]
],
[
[
1151,
62,
112
],
[
112,
... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Sunitinib (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Degarelix (Compound)
Sunitinib may cause a minor interaction that can lim... |
DB00289 | DB11978 | 847 | 124 | [
"DDInter132",
"DDInter822"
] | Atomoxetine | Glasdegib | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
847,
24,
124
]
],
[
[
847,
23,
112
],
[
112,
23,
124
]
],
[
[
847,
24,
79
],
[
79,
24,
124
]
],
[
[
847,
63,
521
],
[
521,
24,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sora... |
DB00004 | DB10429 | 669 | 200 | [
"DDInter499",
"DDInter282"
] | Denileukin diftitox | Candida albicans | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
669,
24,
200
]
],
[
[
669,
24,
1683
],
[
1683,
24,
200
]
],
[
[
669,
25,
976
],
[
976,
24,
200
]
],
[
[
669,
24,
738
],
[
738,
6... | [
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ust... | Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Denileukin diftitox may lead to a major life threatening interaction when taken with Tofacitini... |
DB00252 | DB15091 | 362 | 676 | [
"DDInter1460",
"DDInter1901"
] | Phenytoin | Upadacitinib | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
362,
25,
676
]
],
[
[
362,
25,
283
],
[
283,
24,
676
]
],
[
[
362,
64,
600
],
[
600,
24,
676
]
],
[
[
362,
24,
1040
],
[
1040,
2... | [
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} m... | Phenytoin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Phenytoin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate in... |
DB09065 | DB11915 | 760 | 1,293 | [
"DDInter424",
"DDInter1909"
] | Cobicistat | Valbenazine | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Major | 2 | [
[
[
760,
25,
1293
]
],
[
[
760,
24,
710
],
[
710,
63,
1293
]
],
[
[
760,
63,
401
],
[
401,
24,
1293
]
],
[
[
760,
25,
283
],
[
283,
... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
],
[
"Binimeti... | Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and P... |
DB01067 | DB01583 | 959 | 624 | [
"DDInter826",
"DDInter1075"
] | Glipizide | Liotrix | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Moderate | 1 | [
[
[
959,
24,
624
]
],
[
[
959,
63,
1152
],
[
1152,
1,
624
]
],
[
[
959,
63,
542
],
[
542,
40,
624
]
],
[
[
959,
21,
28898
],
[
28898,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (Compound... |
DB06674 | DB13915 | 908 | 689 | [
"DDInter837",
"DDInter146"
] | Golimumab | Axicabtagene ciloleucel | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express ant... | Major | 2 | [
[
[
908,
25,
689
]
],
[
[
908,
63,
599
],
[
599,
24,
689
]
],
[
[
908,
25,
270
],
[
270,
24,
689
]
],
[
[
908,
24,
1430
],
[
1430,
2... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel
Golimumab may lead to a major life threatening interaction when taken with Ocrelizumab and Ocreliz... |
DB00284 | DB00738 | 1,647 | 485 | [
"DDInter11",
"DDInter1420"
] | Acarbose | Pentamidine | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
1647,
24,
485
]
],
[
[
1647,
18,
9384
],
[
9384,
46,
485
]
],
[
[
1647,
21,
28722
],
[
28722,
60,
485
]
],
[
[
1647,
24,
4
],
[
4,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Acarbose",
"{u} (Compound) downregulates {v} (Gene)",
"TRIB3"
],
[
"TRIB3",
"{u} (Gene) is upregulated by {v} (Co... | Acarbose (Compound) downregulates TRIB3 (Gene) and TRIB3 (Gene) is upregulated by Pentamidine (Compound)
Acarbose (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Pentamidine (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepes... |
DB08908 | DB11703 | 713 | 405 | [
"DDInter564",
"DDInter9"
] | Dimethyl fumarate | Acalabrutinib | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
713,
24,
405
]
],
[
[
713,
63,
139
],
[
139,
24,
405
]
],
[
[
713,
24,
951
],
[
951,
24,
405
]
],
[
[
713,
24,
151
],
[
151,
63,... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Palb... |
DB00827 | DB09154 | 646 | 1,475 | [
"DDInter383",
"DDInter1686"
] | Cinoxacin | Sodium citrate | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
646,
24,
1475
]
],
[
[
646,
25,
1411
],
[
1411,
23,
1475
]
],
[
[
646,
63,
663
],
[
663,
23,
1475
]
],
[
[
646,
24,
428
],
[
428,
... | [
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Cinoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolbutamide"
],
[
"Tolbuta... | Cinoxacin may lead to a major life threatening interaction when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Cinoxacin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may ... |
DB00526 | DB00549 | 1,555 | 522 | [
"DDInter1355",
"DDInter1955"
] | Oxaliplatin | Zafirlukast | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Moderate | 1 | [
[
[
1555,
24,
522
]
],
[
[
1555,
6,
7950
],
[
7950,
45,
522
]
],
[
[
1555,
24,
479
],
[
479,
62,
522
]
],
[
[
1555,
64,
1230
],
[
1230,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Oxaliplatin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound... | Oxaliplatin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Zafirlukast (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Oxaliplatin may le... |
DB00069 | DB09061 | 367 | 1,627 | [
"DDInter946",
"DDInter284"
] | Interferon alfacon-1 | Cannabidiol | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
367,
24,
1627
]
],
[
[
367,
24,
384
],
[
384,
23,
1627
]
],
[
[
367,
24,
467
],
[
467,
24,
1627
]
],
[
[
367,
24,
1613
],
[
1613,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelal... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Si... |
DB09407 | DB13749 | 853 | 1,473 | [
"DDInter1114",
"DDInter1116"
] | Magnesium chloride | Magnesium gluconate | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Magnesium gluconate is a magnesium salt of gluconate. It demonstrates the highest oral bioavailability of magnesium salts and is used as a mineral supplement. Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an... | Moderate | 1 | [
[
[
853,
24,
1473
]
],
[
[
853,
63,
1299
],
[
1299,
24,
1473
]
],
[
[
853,
24,
943
],
[
943,
24,
1473
]
],
[
[
853,
24,
133
],
[
133,
... | [
[
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
]
],
[
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tr... | Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Magnesium chloride may cause a moderate interaction that could exacerbate diseases when t... |
DB00342 | DB08912 | 1,181 | 1,040 | [
"DDInter1770",
"DDInter462"
] | Terfenadine | Dabrafenib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1181,
24,
1040
]
],
[
[
1181,
24,
1612
],
[
1612,
62,
1040
]
],
[
[
1181,
63,
1101
],
[
1101,
23,
1040
]
],
[
[
1181,
25,
478
],
[
478... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexa... |
DB08881 | DB11703 | 868 | 405 | [
"DDInter1925",
"DDInter9"
] | Vemurafenib | Acalabrutinib | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
868,
24,
405
]
],
[
[
868,
63,
1051
],
[
1051,
24,
405
]
],
[
[
868,
64,
690
],
[
690,
24,
405
]
],
[
[
868,
24,
951
],
[
951,
2... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Vemurafenib may lead to a major life threatening interaction when taken with Rifabutin and Rif... |
DB01088 | DB08822 | 714 | 911 | [
"DDInter908",
"DDInter156"
] | Iloprost | Azilsartan medoxomil | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Moderate | 1 | [
[
[
714,
24,
911
]
],
[
[
714,
63,
217
],
[
217,
1,
911
]
],
[
[
714,
24,
1450
],
[
1450,
63,
911
]
],
[
[
714,
24,
549
],
[
549,
24... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"
],
... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interactio... |
DB06636 | DB08895 | 1,623 | 976 | [
"DDInter980",
"DDInter1825"
] | Isavuconazonium | Tofacitinib | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
1623,
24,
976
]
],
[
[
1623,
24,
214
],
[
214,
63,
976
]
],
[
[
1623,
25,
982
],
[
982,
63,
976
]
],
[
[
1623,
63,
86
],
[
86,
2... | [
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
... | Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Isavuconazonium may lead to a major life threatening interaction when taken with Ivosidenib and Ivosid... |
DB00361 | DB00970 | 134 | 0 | [
"DDInter1939",
"DDInter466"
] | Vinorelbine | Dactinomycin | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Moderate | 1 | [
[
[
134,
24,
0
]
],
[
[
134,
6,
4973
],
[
4973,
45,
0
]
],
[
[
134,
18,
7546
],
[
7546,
46,
0
]
],
[
[
134,
7,
9489
],
[
9489,
46,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Vinorelbine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Vinorelbine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dactinomycin (Compound)
Vinorelbine (Compound) downregulates PRCP (Gene) and PRCP (Gene) is upregulated by Dactinomycin (Compound)
Vinorelbine (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Dactinomycin (Compound)
Vinorelbine (... |
DB00285 | DB09268 | 1,100 | 1,662 | [
"DDInter1927",
"DDInter1464"
] | Venlafaxine | Picosulfuric acid | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1100,
24,
1662
]
],
[
[
1100,
24,
484
],
[
484,
63,
1662
]
],
[
[
1100,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
1100,
24,
597
],
[
597,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Venlafaxine may lead to a major life threatening interaction when taken with Cabozantinib and Cabozant... |
DB00047 | DB00575 | 176 | 1,020 | [
"DDInter932",
"DDInter412"
] | Insulin glargine | Clonidine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Moderate | 1 | [
[
[
176,
24,
1020
]
],
[
[
176,
24,
433
],
[
433,
63,
1020
]
],
[
[
176,
24,
590
],
[
590,
24,
1020
]
],
[
[
176,
23,
274
],
[
274,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Clonidine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Acet... |
DB01142 | DB13074 | 1,264 | 877 | [
"DDInter593",
"DDInter1110"
] | Doxepin | Macimorelin | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
1264,
25,
877
]
],
[
[
1264,
62,
112
],
[
112,
23,
877
]
],
[
[
1264,
63,
85
],
[
85,
24,
877
]
],
[
[
1264,
64,
1020
],
[
1020,
... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole"... | Doxepin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine ma... |
DB00934 | DB08881 | 413 | 868 | [
"DDInter1124",
"DDInter1925"
] | Maprotiline | Vemurafenib | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
413,
25,
868
]
],
[
[
413,
6,
12523
],
[
12523,
45,
868
]
],
[
[
413,
7,
7972
],
[
7972,
46,
868
]
],
[
[
413,
7,
6886
],
[
6886,
... | [
[
[
"Maprotiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Maprotiline",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Vemu... | Maprotiline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Vemurafenib (Compound)
Maprotiline (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Vemurafenib (Compound)
Maprotiline (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is downregulated by Vemurafenib (Compound)
Maprot... |
DB06204 | DB06282 | 768 | 516 | [
"DDInter1746",
"DDInter1053"
] | Tapentadol | Levocetirizine | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
768,
24,
516
]
],
[
[
768,
63,
701
],
[
701,
24,
516
]
],
[
[
768,
24,
407
],
[
407,
63,
516
]
],
[
[
768,
64,
593
],
[
593,
24,... | [
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium m... |
DB01265 | DB06674 | 1,477 | 908 | [
"DDInter1757",
"DDInter837"
] | Telbivudine | Golimumab | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
1477,
24,
908
]
],
[
[
1477,
64,
268
],
[
268,
24,
908
]
],
[
[
1477,
63,
458
],
[
458,
24,
908
]
],
[
[
1477,
24,
1487
],
[
1487,
... | [
[
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Telbivudine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon alfa-2b"
],
[
... | Telbivudine may lead to a major life threatening interaction when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole an... |
DB00348 | DB00365 | 254 | 839 | [
"DDInter1300",
"DDInter842"
] | Nitisinone | Grepafloxacin | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Moderate | 1 | [
[
[
254,
24,
839
]
],
[
[
254,
24,
372
],
[
372,
62,
839
]
],
[
[
254,
63,
1101
],
[
1101,
23,
839
]
],
[
[
254,
24,
1362
],
[
1362,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bex... |
DB00381 | DB06292 | 376 | 549 | [
"DDInter79",
"DDInter474"
] | Amlodipine | Dapagliflozin | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
376,
24,
549
]
],
[
[
376,
24,
1344
],
[
1344,
40,
549
]
],
[
[
376,
6,
9842
],
[
9842,
45,
549
]
],
[
[
376,
21,
28898
],
[
28898,
... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Amlodipine (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Dapagliflozin (Compound)
Amlodipine (Compound) causes Constipation (Side Effect... |
DB00674 | DB04868 | 1,516 | 478 | [
"DDInter802",
"DDInter1293"
] | Galantamine | Nilotinib | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1516,
24,
478
]
],
[
[
1516,
6,
8374
],
[
8374,
45,
478
]
],
[
[
1516,
21,
28963
],
[
28963,
60,
478
]
],
[
[
1516,
24,
112
],
[
112,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Galantamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Galantamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Galantamine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metr... |
DB06674 | DB14962 | 908 | 1,363 | [
"DDInter837",
"DDInter1847"
] | Golimumab | Trastuzumab deruxtecan | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes i... | Major | 2 | [
[
[
908,
25,
1363
]
],
[
[
908,
24,
1430
],
[
1430,
24,
1363
]
],
[
[
908,
25,
384
],
[
384,
24,
1363
]
],
[
[
908,
63,
599
],
[
599,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab deruxtecan"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab deruxtecan
Golimumab may lead to a major life threatening interaction when taken with Idelalisib and Idelali... |
DB00238 | DB01259 | 188 | 392 | [
"DDInter1285",
"DDInter1024"
] | Nevirapine | Lapatinib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
188,
24,
392
]
],
[
[
188,
6,
8374
],
[
8374,
45,
392
]
],
[
[
188,
21,
29539
],
[
29539,
60,
392
]
],
[
[
188,
24,
1135
],
[
1135,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Nevirapine (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Lapatinib (Compound)
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol a... |
DB00222 | DB14751 | 245 | 388 | [
"DDInter825",
"DDInter1132"
] | Glimepiride | Mecasermin rinfabate | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH). Mecasermin rinfabate is similar to in that both drugs contain recombinant DNA origin insulin-like growth factor 1 (IGF-1). Mecasermin... | Moderate | 1 | [
[
[
245,
24,
388
]
],
[
[
245,
24,
1144
],
[
1144,
24,
388
]
],
[
[
245,
40,
959
],
[
959,
24,
388
]
],
[
[
245,
63,
1179
],
[
1179,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mecasermin rinfabate"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate
Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interactio... |
DB00888 | DB01041 | 1,001 | 770 | [
"DDInter1133",
"DDInter1789"
] | Mechlorethamine | Thalidomide | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
1001,
25,
770
]
],
[
[
1001,
5,
11555
],
[
11555,
44,
770
]
],
[
[
1001,
21,
28784
],
[
28784,
60,
770
]
],
[
[
1001,
24,
4
],
[
4,
... | [
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Mechlorethamine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) i... | Mechlorethamine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Thalidomide (Compound)
Mechlorethamine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Thalidomide (Compound)
Mechlorethamine may cause a moderate interaction th... |
DB04837 | DB05541 | 649 | 801 | [
"DDInter407",
"DDInter239"
] | Clofedanol | Brivaracetam | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 . | Moderate | 1 | [
[
[
649,
24,
801
]
],
[
[
649,
63,
475
],
[
475,
24,
801
]
],
[
[
649,
1,
820
],
[
820,
24,
801
]
],
[
[
649,
74,
662
],
[
662,
24,
... | [
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brivaracetam"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
... | Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Clofedanol (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could... |
DB00635 | DB00880 | 1,573 | 359 | [
"DDInter1515",
"DDInter360"
] | Prednisone | Chlorothiazide | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Moderate | 1 | [
[
[
1573,
24,
359
]
],
[
[
1573,
24,
1577
],
[
1577,
1,
359
]
],
[
[
1573,
63,
1014
],
[
1014,
1,
359
]
],
[
[
1573,
21,
28748
],
[
28748,... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resemble... |
DB00860 | DB14409 | 891 | 1,129 | [
"DDInter1513",
"DDInter867"
] | Prednisolone | Human adenovirus e serotype 4 strain cl-68578 antigen | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
891,
24,
1129
]
],
[
[
891,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
891,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
891,
40,
251
],
[
251,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Prednisolone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Prednisolone may cause a moderate interaction that could exacerbate diseases when ... |
DB01320 | DB09049 | 651 | 1,135 | [
"DDInter783",
"DDInter1261"
] | Fosphenytoin | Naloxegol | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Major | 2 | [
[
[
651,
25,
1135
]
],
[
[
651,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
651,
63,
1424
],
[
1424,
23,
1135
]
],
[
[
651,
24,
1069
],
[
1069,
... | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} ... | Fosphenytoin may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a minor... |
DB00321 | DB00747 | 21 | 1,442 | [
"DDInter78",
"DDInter1647"
] | Amitriptyline | Scopolamine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Moderate | 1 | [
[
[
21,
24,
1442
]
],
[
[
21,
24,
19
],
[
19,
24,
1442
]
],
[
[
21,
6,
7420
],
[
7420,
45,
1442
]
],
[
[
21,
21,
28766
],
[
28766,
6... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine
Amitriptyline (Compound) binds CHRM4 (Gene) and CHRM4 (Gene) is bound by Scopolamine (Compound)
Amitriptyl... |
DB00535 | DB08938 | 1,145 | 1,384 | [
"DDInter315",
"DDInter1112"
] | Cefdinir | Magaldrate | Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat ... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1145,
24,
1384
]
],
[
[
1145,
1,
665
],
[
665,
24,
1384
]
],
[
[
1145,
24,
428
],
[
428,
63,
1384
]
],
[
[
1145,
24,
1596
],
[
1596,
... | [
[
[
"Cefdinir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Cefdinir",
"{u} (Compound) resembles {v} (Compound)",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} may cause a moderate in... | Cefdinir (Compound) resembles Cefuroxime (Compound) and Cefuroxime may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Cefdinir may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction th... |
DB00193 | DB00619 | 534 | 1,419 | [
"DDInter1841",
"DDInter909"
] | Tramadol | Imatinib | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
534,
24,
1419
]
],
[
[
534,
6,
12523
],
[
12523,
45,
1419
]
],
[
[
534,
7,
3422
],
[
3422,
46,
1419
]
],
[
[
534,
21,
28847
],
[
28847... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Tramadol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Imatinib (Compound)
Tramadol (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Imatinib (Compound)
Tramadol (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Imatinib (Compound)
Tramadol may... |
DB00180 | DB00224 | 1,351 | 215 | [
"DDInter749",
"DDInter917"
] | Flunisolide | Indinavir | Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors. | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Moderate | 1 | [
[
[
1351,
24,
215
]
],
[
[
1351,
24,
798
],
[
798,
1,
215
]
],
[
[
1351,
6,
8374
],
[
8374,
45,
215
]
],
[
[
1351,
21,
28882
],
[
28882,
... | [
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indinavir"
]
],
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
... | Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Indinavir (Compound)
Flunisolide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indinavir (Compound)
Flunisolide (Compound) causes Body temperature increased (Side Eff... |
DB00831 | DB01132 | 1,178 | 1,130 | [
"DDInter1866",
"DDInter1472"
] | Trifluoperazine | Pioglitazone | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1178,
24,
1130
]
],
[
[
1178,
21,
28778
],
[
28778,
60,
1130
]
],
[
[
1178,
1,
851
],
[
851,
63,
1130
]
],
[
[
1178,
24,
688
],
[
688,... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
... | Trifluoperazine (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Pioglitazone (Compound)
Trifluoperazine (Compound) resembles Nefazodone (Compound) and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Trifluoperaz... |
DB00852 | DB01221 | 1,445 | 1,190 | [
"DDInter1545",
"DDInter1007"
] | Pseudoephedrine | Ketamine | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Moderate | 1 | [
[
[
1445,
24,
1190
]
],
[
[
1445,
6,
7390
],
[
7390,
45,
1190
]
],
[
[
1445,
21,
28787
],
[
28787,
60,
1190
]
],
[
[
1445,
24,
222
],
[
22... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Com... | Pseudoephedrine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Ketamine (Compound)
Pseudoephedrine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ketamine (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Sibutr... |
DB00841 | DB01132 | 532 | 1,130 | [
"DDInter577",
"DDInter1472"
] | Dobutamine | Pioglitazone | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
532,
24,
1130
]
],
[
[
532,
21,
28763
],
[
28763,
60,
1130
]
],
[
[
532,
24,
688
],
[
688,
24,
1130
]
],
[
[
532,
35,
480
],
[
480,
... | [
[
[
"Dobutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Dobutamine",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect) is ... | Dobutamine (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Pioglitazone (Compound)
Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Pio... |
DB00630 | DB09322 | 1,485 | 1,114 | [
"DDInter42",
"DDInter1966"
] | Alendronic acid | Zinc sulfate | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Moderate | 1 | [
[
[
1485,
24,
1114
]
],
[
[
1485,
24,
1596
],
[
1596,
23,
1114
]
],
[
[
1485,
24,
428
],
[
428,
62,
1114
]
],
[
[
1485,
1,
1199
],
[
1199,... | [
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
],
... | Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Fe... |
DB00046 | DB09068 | 1,179 | 1,427 | [
"DDInter940",
"DDInter1948"
] | Insulin lispro | Vortioxetine | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
1179,
24,
1427
]
],
[
[
1179,
24,
1220
],
[
1220,
24,
1427
]
],
[
[
1179,
24,
98
],
[
98,
63,
1427
]
],
[
[
1179,
24,
73
],
[
73,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Somat... |
DB00286 | DB06655 | 380 | 5 | [
"DDInter439",
"DDInter1077"
] | Conjugated estrogens | Liraglutide | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
380,
24,
5
]
],
[
[
380,
24,
353
],
[
353,
23,
5
]
],
[
[
380,
40,
559
],
[
559,
24,
5
]
],
[
[
380,
24,
870
],
[
870,
24,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseo... | Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Conjugated estrogens (Compound) resembles Estrone (Compound) and Estrone may cause a moderate inter... |
DB00008 | DB15091 | 491 | 676 | [
"DDInter1407",
"DDInter1901"
] | Peginterferon alfa-2a | Upadacitinib | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
491,
25,
676
]
],
[
[
491,
24,
1430
],
[
1430,
24,
676
]
],
[
[
491,
24,
869
],
[
869,
25,
676
]
],
[
[
491,
25,
1064
],
[
1064,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when take... |
DB10316 | DB11921 | 334 | 1,019 | [
"DDInter1248",
"DDInter492"
] | Mumps virus strain B level jeryl lynn live antigen | Deflazacort | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
334,
25,
1019
]
],
[
[
334,
25,
270
],
[
270,
63,
1019
]
],
[
[
334,
64,
629
],
[
629,
24,
1019
]
],
[
[
334,
25,
1316
],
[
1316,
... | [
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when ... | Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threaten... |
DB00734 | DB11730 | 1,664 | 351 | [
"DDInter1605",
"DDInter1588"
] | Risperidone | Ribociclib | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1664,
25,
351
]
],
[
[
1664,
23,
112
],
[
112,
23,
351
]
],
[
[
1664,
24,
222
],
[
222,
23,
351
]
],
[
[
1664,
24,
283
],
[
283,
... | [
[
[
"Risperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Risperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and S... |
DB06702 | DB09076 | 573 | 1,116 | [
"DDInter731",
"DDInter1899"
] | Fesoterodine | Umeclidinium | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
573,
24,
1116
]
],
[
[
573,
63,
849
],
[
849,
24,
1116
]
],
[
[
573,
24,
1429
],
[
1429,
24,
1116
]
],
[
[
573,
40,
494
],
[
494,
... | [
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and ... |
DB00220 | DB00342 | 798 | 1,181 | [
"DDInter1276",
"DDInter1770"
] | Nelfinavir | Terfenadine | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Major | 2 | [
[
[
798,
25,
1181
]
],
[
[
798,
25,
159
],
[
159,
63,
1181
]
],
[
[
798,
24,
659
],
[
659,
63,
1181
]
],
[
[
798,
24,
1101
],
[
1101,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
... | Nelfinavir may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may... |
DB06688 | DB08904 | 1,430 | 375 | [
"DDInter1677",
"DDInter342"
] | Sipuleucel-T | Certolizumab pegol | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
1430,
24,
375
]
],
[
[
1430,
63,
66
],
[
66,
24,
375
]
],
[
[
1430,
63,
881
],
[
881,
25,
375
]
],
[
[
1430,
24,
398
],
[
398,
6... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Abatacept... |
DB00197 | DB05528 | 1,324 | 1,070 | [
"DDInter1881",
"DDInter1228"
] | Troglitazone | Mipomersen | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
1324,
25,
1070
]
],
[
[
1324,
24,
1250
],
[
1250,
64,
1070
]
],
[
[
1324,
24,
1195
],
[
1195,
25,
1070
]
],
[
[
1324,
63,
168
],
[
168... | [
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopan... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Mipomersen
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may lead t... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.